Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2014; 20(21): 6580-6585
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6580
Prognostic factors in stage IB gastric cancer
Toru Aoyama, Takaki Yoshikawa, Hirohito Fujikawa, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Takanobu Yamada, Shinichi Hasegawa, Kazuhito Tsuchida, Norio Yukawa, Takashi Oshima, Mari S Oba, Satoshi Morita, Yasushi Rino, Munetaka Masuda
Toru Aoyama, Takaki Yoshikawa, Hirohito Fujikawa, Tsutomu Hayashi, Takashi Ogata, Haruhiko Cho, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama 241-0815, Japan
Takanobu Yamada, Shinichi Hasegawa, Kazuhito Tsuchida, Norio Yukawa, Takashi Oshima, Yasushi Rino, Munetaka Masuda, Department of Surgery, Yokohama City University, Yokohama 236-0004, Japan
Mari S Oba, Satoshi Morita, Department of Biostatistics and Epidemiology, Yokohama City University, Yokohama 236-0004, Japan
Author contributions: Aoyama T and Yoshikawa T designed the research; Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H, Yamada T, Hasegawa S, Tsuchida K, Yukawa N, Oshima T, Rino Y and Masuda M performed the research; Oba MS and Morita S contributed new reagents/analytic tools; Oba MS and Morita S analyzed the data; and Aoyama T and Yoshikawa T wrote the paper.
Supported by Non-Governmental Organizations Kanagawa Standard Anti-cancer Therapy Support System
Correspondence to: Dr. Takaki Yoshikawa, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan. yoshikawat@kcch.jp
Telephone: +81-45-3915761 Fax: +81-45-3614692
Received: October 24, 2013
Revised: December 20, 2013
Accepted: January 19, 2014
Published online: June 7, 2014
Processing time: 225 Days and 6.4 Hours
Core Tip

Core tip: This study identified the subset of patients with stage IB gastric cancer with an unfavorable prognosis. Overall survival (OS) rates were examined in 103 patients with stage IB gastric cancer. Both univariate and multivariate analyses demonstrated that tumor location was the only significant prognostic factor. The OS rate was 81.8% at 5-years when the tumor was located in the upper third of the stomach and was 95.5% at 5-years when the tumor was located in the middle or lower third of the stomach (P = 0.0093). Our data may suggest that tumor location is associated with survival in patients with stage IB gastric cancer.